Every 10-Q that Mountain Crest (MCAG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MCAG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MCAG filings page.
Mountain Crest Acquisition Corp. V is a SPAC that has not yet completed a Business Combination and remains in pre-revenue status. For the quarter ended June 30, 2026, it reported net income of $5,178, versus a net loss of $110,574 a year earlier, mainly due to a $100,000 gain on extinguishment of liabilities and $7,506 of interest on its Trust Account. For the first six months of 2026, it recorded a net loss of $108,797, an improvement from a loss of $291,952 for the same period in 2025.
Total assets were $889,852 at June 30, 2026, including $855,537 in the Trust Account and $18,299 of cash outside the trust. Liabilities totaled $3,847,545, driven by a $2,070,000 deferred underwriting fee and $1,550,000 of related-party promissory notes, resulting in a stockholders’ deficit of $3,800,349 and 72,123 shares of common stock classified as redeemable at an aggregate $842,656. The company’s securities were delisted from Nasdaq in November 2024 and now trade on the OTC Pink Market.
Management discloses that it has until November 16, 2026 to consummate a Business Combination, subject to periodic sponsor-funded extensions, and states that mandatory liquidation and dissolution would follow if no deal is completed. Limited working capital and reliance on sponsor loans lead to a conclusion that there is substantial doubt about the company’s ability to continue as a going concern, even as it continues pursuing a previously signed Business Combination Agreement with CUBEBIO Co., Ltd.
Mountain Crest Acquisition Corp. V, a SPAC, reported a Q1 2026 net loss of $113,975, driven mainly by general and administrative expenses of $120,046. Interest income on the Trust Account was modest at $7,392, reflecting its small remaining balance.
Total assets were $986,588 as of March 31, 2026, including $848,031 in the Trust Account and $97,101 of cash held outside the trust. Current liabilities were $1,879,459, largely related-party promissory notes, plus a $2,070,000 deferred underwriting fee, leaving a stockholders’ deficit of $3,802,061. The company has experienced extensive redemptions, with only 72,123 redeemable Public Shares outstanding and 2,873,023 total common shares issued and outstanding as of May 15, 2026.
Management discloses substantial doubt about the company’s ability to continue as a going concern because it must complete a Business Combination by November 16, 2026 or liquidate. Its securities were delisted from Nasdaq in November 2024 and now trade on the OTC Pink Market. The company has a Business Combination Agreement with CUBEBIO Co., Ltd. and is funding ongoing costs through a series of sponsor promissory notes.
Mountain Crest Acquisition Corp. V (MCAG) filed its Q3 2025 report, showing it remains a SPAC pursuing a business combination while trading on the OTC Pink Market following a Nasdaq delisting in November 2024. For the quarter ended September 30, 2025, the company reported a net loss of $66,479 and a nine‑month net loss of $358,431.
Liquidity is tight with cash of $41,172 outside the trust and investments held in the Trust Account of $1,193,968. Total liabilities were $3,907,028, including a $2,070,000 deferred underwriting fee and $1,070,000 related‑party promissory note. Stockholders’ deficit was $(3,802,791). The balance sheet reflects excise taxes payable of $225,426; the company recognized $12,969 in excise‑tax interest and penalties in Q3.
The company disclosed substantial doubt about its ability to continue as a going concern, citing the need to complete a business combination by November 16, 2026 (with required deposits for extensions) or redeem public shares and liquidate. Redemptions on November 8, 2024 totaled 418,217 shares for $4,736,743. As of November 14, 2025, 2,873,023 common shares were outstanding. The company states it continues to pursue a business combination.